NasdaqGS - Nasdaq Real Time Price USD

Schrödinger, Inc. (SDGR)

Compare

19.29

-1.04

(-5.12%)

At close: January 10 at 4:00:01 PM EST

19.44

+0.15

+(0.78%)

After hours: January 10 at 5:56:13 PM EST

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, December 17, 2024--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 12, 2024, the company granted restricted stock units (RSUs) with respect to 8,365 shares of the company’s common stock to six newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducemen

Business Wire 24 days ago

SDGR
-5.12%
Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference

NEW YORK, November 20, 2024--Schrödinger today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference.

Business Wire last month

SDGR
-5.12%
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

NEW YORK, November 18, 2024--Schrödinger broadens and accelerates predictive toxicology initiative.

Business Wire last month

SDGR
-5.12%
Schrödinger Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Schrödinger ( NASDAQ:SDGR ) Third Quarter 2024 Results Key Financial Results Revenue: US$35.3m (down 17% from 3Q 2023...

Simply Wall St. last month

SDGR
-5.12%
Schrodinger announces expanded license agreement with Novartis

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple development candidates into Novartis’s portfolio for further development. The companies also announced an expanded three-year software agreement that substantially increases Novartis’s access to Schrodinger’s computational predictive modeling technology and enterprise informatics platform. This expanded access enables Novartis to deploy Schrodinger’s full suite of drug discov

TipRanks last month

NVS

NVSEF

SDGR
-5.12%
Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...

Despite a decline in total revenue, Schrodinger Inc (SDGR) strengthens its financial position with a major Novartis collaboration and increased software revenue.

GuruFocus.com last month

SDGR
-5.12%
NVS
Q3 2024 Schrodinger Inc Earnings Call

Q3 2024 Schrodinger Inc Earnings Call

Thomson Reuters StreetEvents last month

NVS

SDGR
-5.12%
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and license agreement with Novartis AG (NYSE:NVS) to advance multiple development candidates. The companies also announced an extended three-year agreement that grants Novartis broad access to Schrödinger’s predictive modeling and informatics platform, enabling large-scale integration across research sites. Karen Akinsanya, president of R&D, therapeutics at Schrödinger, said, “We

Benzinga last month

NVS

SDGR
-5.12%
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates

Schrodinger (SDGR) delivered earnings and revenue surprises of -30% and 13.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

SDGR
-5.12%
PHR
Schrödinger Reports Third Quarter 2024 Financial Results

NEW YORK, November 12, 2024--Schrödinger today announced financial results for the third quarter of 2024 and provided a business update.

Business Wire last month

SDGR
-5.12%
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

NEW YORK, November 12, 2024--Schrödinger today announced a multi-target collaboration and expanded software licensing agreement with Novartis.

Business Wire last month

SDGR
-5.12%
Schrödinger to Present at Jefferies London Healthcare Conference

NEW YORK, November 04, 2024--Schrödinger today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference.

Business Wire 2 months ago

SDGR
-5.12%
Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

NEW YORK, October 31, 2024--Schrödinger will report its third quarter 2024 financial results on Tuesday, November 12, 2024, before the financial markets open.

Business Wire 2 months ago

SDGR
-5.12%
iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?

iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 2 months ago

IRTC

SDGR
-5.12%
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

NEW YORK, October 23, 2024--Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. The preclinical data also show that SGR-3515 has a favorable ph

Business Wire 2 months ago

SDGR
-5.12%
Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

NEW YORK, October 09, 2024--Schrödinger (Nasdaq: SDGR) today announced that new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, and the company’s PRMT5-MTA inhibitor program, will be presented during poster sessions at the 36th EORTC-NCI-AACR Symposium (ENA 2024) taking place October 23-25, 2024 in Barcelona, Spain.

Business Wire 3 months ago

SDGR
-5.12%
Schrödinger, Inc. (SDGR): A Bull Case Theory

We came across a bullish thesis on Schrödinger, Inc. (SDGR) on Value Degen’s Substack by Unemployed Value Degen. In this article we will summarize the bulls’ thesis on SDGR. Schrödinger, Inc. (SDGR) share was trading at $19.62 as of Sept 17th. Schrödinger (SDGR) is emerging as a compelling player in the intersection of software and biotech. Amid […]

Insider Monkey 3 months ago

SDGR
-5.12%
Schrödinger, Inc. (SDGR): Among The Best Medical AI Companies

We recently compiled a list of the 10 Best Medical AI Companies. In this article, we are going to take a look at where Schrödinger, Inc. (NASDAQ:SDGR) stands against the other medical AI companies. The Need for AI in Healthcare Generally, when you hear the term “artificial intelligence,” your mind jumps straight to semiconductor and big […]

Insider Monkey 4 months ago

SDGR
-5.12%
Schrödinger to Present at Morgan Stanley Global Healthcare Conference

NEW YORK, August 14, 2024--Schrödinger today announced that management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference.

Business Wire 4 months ago

SDGR
-5.12%
The 3 Best Med Tech Stocks to Buy Now

According to the Advanced Medical Technology Association, med tech is defined as “companies that develop, manufacture, and distribute the technologies, devices, equipment, diagnostic tests, and health information systems.” The organization reports that these firms favorably change health care with “earlier disease detection, less-invasive procedures, and more effective treatments.” One rapidly emerging section of med tech is artificial intelligence, which is enabling the drug discovery process t

InvestorPlace 5 months ago

SDGR
-5.12%
RXST

TWST
-3.37%

Performance Overview

Return	SDGR	S&P 500
YTD	+2.50%	-1.35%
1-Year	-36.42%	+22.51%
3-Year	-39.59%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Schrödinger, Inc. (SDGR)

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Schrödinger Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Schrodinger announces expanded license agreement with Novartis

Schrodinger Inc (SDGR) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and ...

Q3 2024 Schrodinger Inc Earnings Call

Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Misses Revenue Estimates

Schrödinger Reports Third Quarter 2024 Financial Results

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

Schrödinger, Inc. (SDGR): A Bull Case Theory

Schrödinger, Inc. (SDGR): Among The Best Medical AI Companies

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

The 3 Best Med Tech Stocks to Buy Now

Performance Overview